Novo Nordisk: Undervalued Despite Strong Growth Trend And Solid Market Share [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
Novo Nordisk's diversified GLP-1 portfolio, including Rybelsus and pending pill versions, positions it well against competitors and broadens its addressable market. Consistent double-digit revenue and profit growth, plus strong Q2 2025 expectations, reflect robust demand and effective cost management. NVO trades at a significant discount to Eli Lilly, offering nearly 38% upside; I rate it a buy based on market leadership and undervaluation. Zolak/iStock via Getty Images Thesis Statement I am bullish on Novo Nordisk A/S (NYSE: NVO ), driven by its market share (globally) in the GLP-1 market. In this market leadership, NVO's Ozempic dominates GLP-1 sales by This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (othe
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- GLP-1 Drugs Quietly Reshape How Americans Shop for Food, Study Finds [Yahoo! Finance]Yahoo! Finance
- Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways [Yahoo! Finance]Yahoo! Finance
- Should You Invest in Ozempic Maker Novo Nordisk in 2026? [Yahoo! Finance]Yahoo! Finance
- Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access [Yahoo! Finance]Yahoo! Finance
- Health care will get more expensive for some in 2026 — and cheaper for others [MSNBC.com]MSNBC.com
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website